LBRX net incomeQ3 2026-$59.07M
LBRX net income was -$59.07M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$3.56M a year earlier. For the full fiscal 2025 it was -$25.20M, compared with -$63.10M in fiscal 2024.
LB Pharmaceuticals Inc (LBRX) financials
For the twelve months ended Sep 30, 2026, LB Pharmaceuticals Inc reported -$141.19M of net income.
- Net income, TTM
- -$141.19M
- Free cash flow, TTM
- -$143.82M
- Cash
- $215.07M
- Market cap
- $1.46B
FY2024FY2025
FY2024FY2025
LBRX revenue and earnings growth
LBRX EPSQ3 2026-$1.79
LBRX diluted EPS was -$1.79 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$3.13.
LBRX free cash flowQ3 2026-$64.36M
LBRX free cash flow was -$64.36M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$3.37M a year earlier. For the full fiscal 2025 it was -$35.26M, compared with -$53.82M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Research and development | $16.74M | $51.17M |
| Selling, general and admin | $13.66M | $13.66M |
| Pre-tax income | -$25.20M | -$63.10M |
| Income tax | $1.0K | $1.0K |
| Net income | -$25.20M | -$63.10M |
| EPS, basic | -$3.13 | -$176.15 |
| EPS, diluted | -$3.13 | -$176.15 |
| Diluted shares | 8.0M | 358,229 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $250.17M | $22.98M |
| Short-term investments | $45.04M | $5.02M |
| Current assets | $308.43M | $28.88M |
| Total assets | $312.93M | $33.53M |
| Current liabilities | $7.44M | $8.11M |
| Total liabilities | $11.62M | $13.83M |
| Shareholders' equity | $301.31M | -$94.55M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$35.21M | -$53.05M |
| Capital expenditures | $52.0K | $769.0K |
| Free cash flow | -$35.26M | -$53.82M |
| Investing cash flow | -$39.89M | $23.23M |
| Financing cash flow | $302.56M | $38.31M |
| Stock-based compensation | $4.19M | $3.09M |
| Depreciation and amortization | $321.0K | $91.0K |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $51.52M | $44.15M | $14.64M | $8.48M | $2.42M | $2.42M | $3.42M | $376.0K | $10.66M | - | - |
| Selling, general and admin | $10.98M | $9.77M | $7.46M | $5.39M | $2.83M | $2.44M | $3.01M | $5.16M | $5.42M | - | - |
| Pre-tax income | -$59.07M | -$51.60M | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.31M | -$5.07M | -$14.18M | - | - |
| Income tax | $0 | $0 | $0 | $1.0K | $0 | $0 | $0 | $1.0K | $0 | - | - |
| Net income | -$59.07M | -$51.60M | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.31M | -$5.07M | -$14.18M | -$27.63M | -$16.22M |
| EPS, basic | -$1.79 | -$1.71 | -$0.67 | - | -$0.61 | -$13.58 | -$14.79 | - | -$39.49 | - | - |
| EPS, diluted | -$1.79 | -$1.71 | -$0.67 | - | -$0.61 | -$13.58 | -$14.79 | - | -$39.49 | - | - |
| Diluted shares | 33.1M | 30.1M | 28.2M | - | 5.8M | 358,811 | 358,777 | - | 359,079 | - | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $215.07M | $283.11M | $320.68M | $250.17M | $269.74M | - | - | $22.98M | - | - | - |
| Short-term investments | $188.69M | $44.68M | $44.96M | $45.04M | $44.73M | - | - | $5.02M | - | - | - |
| Current assets | $447.12M | $355.30M | $389.07M | $308.43M | $316.40M | - | - | $28.88M | - | - | - |
| Total assets | $453.37M | $361.69M | $393.48M | $312.93M | $320.75M | - | - | $33.53M | - | - | - |
| Current liabilities | $30.25M | $23.56M | $10.91M | $7.44M | $6.65M | - | - | $8.11M | - | - | - |
| Total liabilities | $35.73M | $29.34M | $14.79M | $11.62M | $10.53M | - | - | $13.83M | - | - | - |
| Shareholders' equity | $417.64M | $332.35M | $378.69M | $301.31M | $310.22M | -$103.87M | -$99.34M | -$94.55M | -$91.45M | -$77.44M | -$50.45M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$64.29M | -$37.63M | -$23.29M | -$18.10M | -$3.37M | -$5.60M | -$8.13M | -$5.67M | - | - | - |
| Capital expenditures | $70.0K | $363.0K | $32.0K | $40.0K | $0 | -$9.0K | $21.0K | $238.0K | - | - | - |
| Free cash flow | -$64.36M | -$37.99M | -$23.32M | -$18.14M | -$3.37M | -$5.61M | -$8.15M | -$5.90M | - | - | - |
| Investing cash flow | -$144.65M | $89.0K | -$32.0K | -$40.0K | -$44.84M | $9.0K | $4.98M | $13.54M | - | - | - |
| Financing cash flow | $140.92M | -$19.0K | $93.83M | -$1.17M | $303.73M | $0 | $0 | $0 | - | - | - |
| Stock-based compensation | $3.67M | $4.90M | $2.57M | $2.34M | $881.0K | $335.0K | $634.0K | $2.28M | - | - | - |
Key ratios
Source: XBRL data LB Pharmaceuticals Inc files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
LBRX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| LBRX | - | - | -$141.19M | - | $1.46B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
LBRX FAQ
5 questionsIs LBRX profitable?
No. LB Pharmaceuticals Inc reported a net loss of $141.19M for the twelve months ended Sep 30, 2026.How much cash and debt does LBRX have?
LB Pharmaceuticals Inc reported $215.07M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is LBRX free cash flow?
LB Pharmaceuticals Inc generated -$143.82M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$143.31M less capital expenditures.When did LBRX last report financial results?
The latest statements here come from LB Pharmaceuticals Inc's 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this LBRX financial data come from?
Quantisnow builds these statements from the structured XBRL data LB Pharmaceuticals Inc files with the SEC. It is provided for information only and is not investment advice.